反式-1-(4-羟基环己基)-4-(4-氟苯基)-5-(2-甲氧基嘧啶-4-基)咪唑
反式-1-(4-羟基环己基)-4-(4-氟苯基)-5-(2-甲氧基嘧啶-4-基)咪唑
反式-1-(4-羟基环己基)-4-(4-氟苯基)-5-(2-甲氧基嘧啶-4-基)咪唑 性质
| 熔点 | 206-207.2 °C |
|---|---|
| 储存条件 | 2-8°C |
| 溶解度 | 二甲基亚砜：11 毫克/毫升 |
| 形态 | 白色固体 |
| 颜色 | 白色 |
| InChI | InChI=1S/C20H21FN4O2/c1-27-20-22-11-10-17(24-20)19-18(13-2-4-14(21)5-3-13)23-12-25(19)15-6-8-16(26)9-7-15/h2-5,10-12,15-16,26H,6-9H2,1H3/t15-,16- |
| InChIKey | ZQUSFAUAYSEREK-WKILWMFISA-N |
| SMILES | [C@@H]1(O)CC[C@@H](N2C=NC(C3=CC=C(F)C=C3)=C2C2C=CN=C(OC)N=2)CC1 |
反式-1-(4-羟基环己基)-4-(4-氟苯基)-5-(2-甲氧基嘧啶-4-基)咪唑 用途与合成方法
| Target | Value |
|
p38α
(Cell-free assay) | 44 nM |
|
p38β
(Cell-free assay) | 44 nM |
SB 239063 (0.1–10 μM ; 29 hours, 47 hours) increases apoptosis of eosinophils in a dose-related in the presence of 10 pM IL-5 at every time point from 21 hours onwards.
SB 239063 potently inhibits IL-1 and TNF- a production in LPS-stimulated human peripheral blood monocytes with IC
50
values of 120 nM and 350 nM, respectively.
Apoptosis Analysis
| Cell Line: | Eosinophils (guinea pig BALs) |
| Concentration: | 0.1μM, 1μM, 10μM |
| Incubation Time: | 29 hours, 47 hours |
| Result: | Increased apoptosis of eosinophils in a dose-related in the presence of 10 pM IL-5 at every time point from 21 hours onwards. |
SB 239063 (12 mg/kg; p.o.; 1 hour before and 4 hours after OA challenge; b.i.d. for 3 days) significantly inhibits the resultant antigen-induced airway eosinophilia.
SB 239063 (12 mg/kg; p.o.) almost abolishes ovalbumin (OA)-induced airway eosinophilia (~ 93% inhibition) by inhalation.
SB 239063 is a potent inhibitor of LPS-induced TNF-alpha production in the mouse peritoneal cavity with an EC
50
of 5.8 mg/kg (2.8–10.3; 95% CL).
| Animal Model: | Male BALB/c mice (18–20 g) |
| Dosage: | 12 mg/kg |
| Administration: | Oral administration; 1 h before and 4 h after OA challenge; bis in die for 3 days |
| Result: | Significantly inhibited the resultant antigen-induced airway eosinophilia. |
![Cyclohexanone, 4-[4-(4-fluorophenyl)-5-(2-methoxy-4-pyrimidinyl)-1H-imidazol-1-yl]-](/CAS/20210305/GIF/193551-20-1.gif)
193551-20-1
193551-21-2
以化合物（CAS: 193551-20-1）为起始原料，合成(1r,4r)-rel-4-(4-(4-氟苯基)-5-(2-甲氧基嘧啶-4-基)-1H-咪唑-1-基)环己醇的一般步骤如下： 实施例2：反式-1-(4-羟基环己基)-4-(4-氟苯基)-5-(2-甲氧基嘧啶-4-基)咪唑的合成 向实施例1（j）中制备的化合物溶液（0.099 g，溶解于MeOH/THF（1 mL，体积比1:1）中，对应0.27 mmol）加入NaBH4溶液（1 mL，1 M溶液。该NaBH4溶液通过将0.10 g NaBH4、MeOH（2.5 mL）和25% NaOMe的MeOH溶液（0.2 mL）混合制备而成）。反应混合物搅拌10分钟后，用饱和Na2CO3溶液淬灭反应，随后蒸发除去溶剂。残余物通过从MeOH/H2O混合溶剂中重结晶纯化，得到目标产物(1r,4r)-rel-4-(4-(4-氟苯基)-5-(2-甲氧基嘧啶-4-基)-1H-咪唑-1-基)环己醇，为白色针状晶体（0.063 g，收率63%）。产物的熔点为188-190℃。
参考文献：
[1] Patent: US6329526, 2001, B1
反式-1-(4-羟基环己基)-4-(4-氟苯基)-5-(2-甲氧基嘧啶-4-基)咪唑 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026-06-06 | B5898 | SB 239063 | 193551-21-2 | 5mg | 140 |
| 2026-06-05 | HY-11068 | 反式-1-(4-羟基环己基)-4-(4-氟苯基)-5-(2-甲氧基嘧啶-4-基)咪唑 | 193551-21-2 | 5mg | 1310 |
